MedTrace Logo

Tau And Connectomics In TES Study

NCT05490576 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-02-28

No results posted yet for this study

Summary

This pilot study aims to assess if participants that meet the criteria for a TES diagnosis have a specific tau deposition profile on PET scanning using the PET tau binding ligand - \[18F\] PI-2620. It is hoped this study will highlight potential diagnostic tests of TES diagnosis, the in-life correlate of CTE.

Conditions

Interventions

RADIATION

[18F] PI-2620 Tau Ligand

Tau binding ligand

Sponsors & Collaborators

  • Omniscient Neurotechnology

    collaborator INDUSTRY

  • Life Molecular Imaging GmbH

    collaborator INDUSTRY

  • Macquarie University, Australia

    lead OTHER

Principal Investigators

  • Rowena Mobbs, MBBS, PhD · MQ Health

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-03
Primary Completion
2023-05-30
Completion
2024-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05490576 on ClinicalTrials.gov